Table II.

Summary of anti-T_H2 approaches and their effects on AEs and asthma-related outcomes

Target	Agent	Reference	Main findings
IgE	Antibody	Teach et al51 Busse et al96	Reduced AE frequency and in 82 restored IFN-α responses to rhinovirus in PBMCs
IL-5	Antibody	Nair et al88 Pavord et al89 Castro et al91	Reductions of 52% and 58% in AE rates and increased time to AEs by 8 weeks in patients with eosinophilic asthma
IL-4	Variant protein	Wenzel et al92	Improved FEV1 during allergen challenge in atopic asthmatic patients
IL-13	Antibody	Corren et al86	Reduction of 60% in AE rate in TH2-high asthmatic patients
IL-5Rα	Antibody	Castro et al90	Reduction of 57% in AE rate in patients with eosinophilic asthma
IL-4Rα	Antibody	Wenzel et al87	Reduction of 87% in AE rates in patients with severe eosinophilic asthma
CRTH2	Small molecule	Pettipher et al93 Gonem et al94	Increased FEV1 and reduced eosinophilic airway inflammation in patients with eosinophilic asthma
GATA-3	DNAzyme	Krug et al95	Increased FEV1, reduced eosinophil numbers, and reduced IL-5 levels in patients with eosinophilic asthma

CRTH2, Chemoattractant receptor-homologous molecule expressed on T_H2 cells; IL-4Rα, IL-4 receptor α; IL-5Rα, IL-5 receptor α.